NASDAQ:SKYE Skye Bioscience Q1 2026 Earnings Report $0.77 0.00 (-0.31%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Skye Bioscience EPS ResultsActual EPS-$0.32Consensus EPS -$0.29Beat/MissMissed by -$0.03One Year Ago EPSN/ASkye Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASkye Bioscience Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Skye Bioscience Earnings HeadlinesSkye Bioscience Expands Authorized Shares After Shareholder ApprovalMay 29 at 6:31 PM | tipranks.comFY2026 EPS Estimate for Skye Bioscience Increased by AnalystMay 25, 2026 | americanbankingnews.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…June 1 at 1:00 AM | Paradigm Press (Ad)Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 24, 2026 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Shares Up 6% - Here's WhyMay 21, 2026 | americanbankingnews.comSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1May 20, 2026 | globenewswire.comSee More Skye Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email. Email Address About Skye BioscienceSkye Bioscience (NASDAQ:SKYE) is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure. Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies. By targeting CB1 receptors in ocular tissues, the company aims to deliver localized efficacy while minimizing systemic exposure. Preclinical studies have demonstrated promising pharmacokinetic and pharmacodynamic profiles, supporting the potential for twice-daily topical administration and rapid onset of action. Founded in 2018, Skye Bioscience has assembled a multidisciplinary leadership team with expertise in pharmacology, medicinal chemistry and ophthalmology. The company collaborates with contract research organizations and academic partners to advance its clinical programs through regulatory milestones and into human trials. As a Nasdaq-listed entity under the symbol SKYE, Skye Bioscience is positioning itself at the forefront of cannabinoid-derived therapeutics for eye health.View Skye Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysBest Buy’s AI Laptop Boost Sparks Hope for a BBY TurnaroundWas Hormel’s Q2 Earnings Report the Turnaround Investors Needed? Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
